Last reviewed · How we verify
Polypharmacy
Polypharmacy is a Small molecule drug developed by Ottawa Hospital Research Institute. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Polypharmacy |
|---|---|
| Sponsor | Ottawa Hospital Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Population Health Approach to Optimizing Medications in Older Adults (NA)
- INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients (NA)
- Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (NA)
- Decreasing Polypharmacy in Older Adults With Curable Cancers Trial (PHASE1, PHASE2)
- Risk-Based Geriatric Assessment-Driven Management in Older Patients Starting Chemotherapy (NA)
- Resilience and Equity in Aging, Cancer, and Health (REACH) (NA)
- PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics
- Preemptive Pharmacogenomics Testing Among Geriatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polypharmacy CI brief — competitive landscape report
- Polypharmacy updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI
Frequently asked questions about Polypharmacy
What is Polypharmacy?
Who makes Polypharmacy?
What development phase is Polypharmacy in?
Related
- Manufacturer: Ottawa Hospital Research Institute — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing